Director/PDMR Shareholding

RNS Number : 6123X

Oxford Biomedica PLC

13 August 2018

 

PDMR Dealings / Market Share Sale

Oxford, UK - 13 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Kyriacos Mitrophanous, Chief Scientific Officer, exercised 13,395 options at 50p ("Ordinary Shares") in the Company on 09 August 2018 and sold all the resulting shares at 904.416p. Following this transaction Kyriacos Mitrophanous holds 164,332 options in the Company.

375 options were exercised at 101.5p and all the resulting shares were sold at 904.416p by Kyriacos Mitrophanous wife (Pippa Radcliffe) and are therefore considered a beneficial holding of Kyriacos Mitrophanous.

The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Kyriacos Mitrophanous
2.	Reason for the notification
a.	Position/status	Chief Scientific Officer
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford BioMedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Ordinary Shares of 50p each  ISIN: GB00BDFBVT43
b.	Nature of the transaction	Exercise of Options
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.50	13,395
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	13,395  £0.50  £6,697.5
f.	Date of the transaction	2018-08-13
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Kyriacos Mitrophanous
2.	Reason for the notification
a.	Position/status	Chief Scientific Officer
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford BioMedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Ordinary Shares of 50p each  ISIN: GB00BDFBVT43
b.	Nature of the transaction	Disposal
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£9.04416	13,395
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	13,395  £9.04416  £121,146.52
f.	Date of the transaction	2018-08-13
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Pippa Radcliffe
2.	Reason for the notification
a.	Position/status	Person closely associated with Kyriacos Mitrophanous, Chief Scientific Officer
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford BioMedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Ordinary shares of 50p each  ISIN: GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£1.015	375
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	375  £101.5  £380.63
f.	Date of the transaction	2018-08-13
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the person discharging material responsibilities/person closely                 associated
a.	Name	Pippa Radcliffe
2.	Reason for the notification
a.	Position/status	Person closely associated with Kyriacos Mitrophanous, Chief Scientific Officer
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford BioMedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Disposal
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£9.04416	375
e.	Aggregated information ·      Aggregated volume ·      Price ·      Aggregated total	375  £9.04416  £3,391.5
f.	Date of the transaction	2018-08-13
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson,  Chief Executive Officer Stuart Paynter, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

DSHGCGDILSBBGIX